EDP-305 - 10mM in DMSO , CAS No.1933507-63-1

CAS: 1933507-63-1 Cat. No.: E654711 Formule: C₃₆H₅₈N₂O₅S Poids moléculaire: 630.92 PubChem CID: 156583184

QUALITÉ & PURETÉ 10mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Vue d’ensemble

EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC 50 values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research

In Vitro

EDP‐305 (10 μM, 72 h) directly activates FXR in liver hepatoctyes but not stellate cells. EDP-305 (0-5 μM, 16 h) increases the expression of the FXR target gene, SHP, and downregulates CYP7A1 expression in HepaRG hepatocytes. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: Hepatic stellate cell (HSC) lines, primary HSCs and hepatocytes Concentration: 10 μM Incubation Time: 72 h Result: Induced mRNA expression of SHP and FGF19 in human hepatocytes, and elicited no induction of downstream targets SHP or FGF15/19 in stellate lines. RT-PCRCell Line: HepaRG hepatocytes Concentration: 0.05, 0.1, 0.5, 1, 5, 10, 50, 100, 500, 1000, 5000 nM Incubation Time: 16 h Result: Dose-dependently increased the expression of the FXR target gene, SHP, and downregulated CYP7A1 expression in HepaRG hepatocytes.

In Vivo

EDP‐305 (0-30 mg/kg, Oral gavage, daily for 2 weeks) reduces serum markers of liver injury, and reduces liver fibrosis in a dose-dependent manner in BDL rats . EDP‐305 (0-30 mg/kg, Oral gavage, daily for 6 weeks) reduces liver fibrosis in a dose-dependent manner in CDAHFD mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male CD rats (underwent BDL, n=24, n=8 for each group) Dosage: 0, 10 and 30 mg/kg Administration: Oral gavage, daily, started on day 4 after BDL and continued until days 17-18 Result: Significantly reduced alanine aminotransferase and aspartate aminotransferase. Showed a dose-dependent reduction in CPA. Reduced hydroxyproline levels in whole liver tissue samples. Reduced messenger RNA (mRNA) relative quantification (RQ) for both Col1a1 and actin, alpha 2, smooth muscle, aorta (Acta2). Animal Model: Male C57BL/6 mice (n = 24, fed a CDAHFD consisting of 60% kcal fat and 0.1% methionine) Dosage: 0, 10 and 30 mg/kg Administration: Oral gavage, daily, started at the beginning of week 6 on the diet and were continued until week 12 Result: Reduced serum triglycerides, and significantly reduced hydroxyproline and MR liver signal intensity in a dose-dependent manner. Showed a dose‐dependent reduction in mRNA expression of lysyl oxidase genes Lox and Loxl1-4.

IC50& Target:IC50: 8 ± 3 nM (Full-length FXR in HEK cells), 34 ± 8 nM (Chimeric FXR in CHO cells), >15000 nM (TGR5 in CHO cells)

Spécifications

Spécifications et pureté

10mM in DMSO

Mécanismes biochimiques et physiologiques

EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC 50 values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be

Conditions de stockage de stockage

Store at -80°C

Expédié en

Dry ice packs + Cold packs

Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.

Type d'action

ACTIVATOR

Noms et identifiants

PubChem CID

156583184

Poids moléculaire

630.92